NCT04123418: Phase 1: A Study of WVT078 in Patients With Multiple Myeloma (MM)

RRMM

NCT04123418: Phase 1: A Study of WVT078 in Patients With Multiple Myeloma (MM)

A Study of WVT078 in Patients With Multiple Myeloma (MM)

The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)

Sponsor

Novartis Pharmaceuticals

Multiple Locations

International Study

---

ClinicalTrials.gov Identifier: NCT04123418

Official Title: A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma